News & Updates

COVID-19 variants carry no increased autoimmune sequelae risk
COVID-19 variants carry no increased autoimmune sequelae risk
16 Sep 2024 byJairia Dela Cruz

COVID-19 variants delta and omicron BA.1 or BA.2 do not pose a substantial threat of long-term autoimmune complications, except for a modest elevation in inflammatory bowel disease and bullous skin disorders among hospitalized patients during the omicron predominance in Singapore, as shown in a study.

COVID-19 variants carry no increased autoimmune sequelae risk
16 Sep 2024
Fewer CV events after COVID-19 vaccine-related myocarditis
Fewer CV events after COVID-19 vaccine-related myocarditis
13 Sep 2024 byElvira Manzano

In a nationwide French cohort study, myocarditis attributed to COVID-19 mRNA vaccination causes fewer cardiovascular (CV) events at 18 months of follow-up than that attributed to SARS-CoV-2 infection or myocarditis of conventional aetiologies.

Fewer CV events after COVID-19 vaccine-related myocarditis
13 Sep 2024
Aiming for clinical remission in severe asthma
Aiming for clinical remission in severe asthma
13 Sep 2024 byProf. Ken Ka-Pang Chan, Department of Medicine and Therapeutics, Chinese University of Hong Kong

The introduction of targeted biologic therapies has revolutionized the management of severe asthma, where clinical remission is now viewed as a realistic treatment goal. In an interview with MIMS Doctor, Professor Ken Ka-Pang Chan of the Department of Medicine and Therapeutics, the Chinese University of Hong Kong, discussed updates in the Global Initiative for Asthma (GINA) 2024 Report that reflect recent research findings on clinical remission with biologic therapy. He further highlighted how tezepelumab, a first-in-class monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), may help achieve this goal through its broad action on multiple downstream inflammatory pathways involved in asthma pathophysiology.

Aiming for clinical remission in severe asthma
13 Sep 2024